Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 26134 | $21,296,463,036 |
Sells | 80005 | $192,729,177,115 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
05 Mar 2024 16:39 | XMTR | Xometry Inc | WEYMOUTH KATHARINE | Director | 04 Mar 2024 | Purchase | 500 | 16.8553 | 8,428 | D |
14 Jun 2023 16:46 | XM | Qualtrics International Inc | STUCKI BRIAN | See Remarks | 12 Jun 2023 | Sale | 2,398 | 18.07 | 43,332 | D |
28 Jun 2023 16:35 | XM | Qualtrics International Inc | STUCKI BRIAN | See Remarks | 26 Jun 2023 | Sale | 12,000 | 18.14 | 217,680 | D |
05 Jun 2023 19:37 | XM | Qualtrics International Inc | MCMURRAY BILL | Chief Revenue Officer | 01 Jun 2023 | Sale | 15,000 | 18.062 | 270,930 | D |
03 Apr 2024 18:50 | XLO | Xilio Therapeutics Inc | GILEAD SCIENCES, INC. | 10% | 02 Apr 2024 | Purchase | 485,250 | 0.76 | 368,790 | D |
16 Jan 2024 18:16 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 11 Jan 2024 | Sale | 1,566 | 0.87 | 1,362 | D |
16 Jan 2024 18:16 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 12 Jan 2024 | Sale | 1,540 | 0.83 | 1,278 | D |
16 Jan 2024 18:16 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 11 Jan 2024 | Sale | 569 | 0.87 | 495 | I |
16 Jan 2024 18:16 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 12 Jan 2024 | Sale | 560 | 0.83 | 465 | I |
09 Feb 2024 16:33 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 08 Feb 2024 | Sale | 733 | 0.64 | 469 | D |
09 Feb 2024 16:33 | XLO | Xilio Therapeutics Inc | ATLAS VENTURE FUND XI, L.P. | 10% | 08 Feb 2024 | Sale | 267 | 0.64 | 171 | I |
21 Mar 2024 14:06 | XIVYX | Institutional Investment Strategy Fund | GHODOOSI ARASH | President, Principal Executive | 19 Mar 2024 | Purchase | 989.1 | 10.11 | 10,000 | D |
21 Mar 2024 14:06 | XIVYX | Institutional Investment Strategy Fund | GHODOOSI ARASH | President, Principal Executive | 20 Mar 2024 | Purchase | 39,254.2 | 10.19 | 400,000 | D |
29 Mar 2024 12:52 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 27 Mar 2024 | Purchase | 33,179.8 | 10.21 | 338,765 | D |
29 Mar 2024 12:52 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 27 Mar 2024 | Purchase | 28,903 | 10.21 | 295,100 | I |
29 Mar 2024 12:52 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 27 Mar 2024 | Purchase | 21,812 | 10.21 | 222,700 | I |
29 Mar 2024 12:52 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 27 Mar 2024 | Purchase | 4,113.6 | 10.21 | 42,000 | I |
15 Apr 2024 13:05 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer | 01 Apr 2024 | Purchase | 779 | 10.2 | 7,946 | D |
15 Apr 2024 13:05 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer | 08 Apr 2024 | Purchase | 0.4 | 10.17 | 4 | D |
15 Apr 2024 13:05 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer | 01 Apr 2024 | Purchase | 15,616.2 | 10.2 | 159,286 | D |
15 Apr 2024 13:05 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer | 08 Apr 2024 | Purchase | 10 | 10.17 | 101 | D |
22 Apr 2024 12:45 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 18 Apr 2024 | Purchase | 4,804.9 | 10.01 | 48,097 | D |
03 May 2024 17:14 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer, 10% | 30 Apr 2024 | Purchase | 1.5 | 10.03 | 15 | D |
09 May 2024 15:02 | XIVYX | Institutional Investment Strategy Fund | O'NEIL BRIAN STEPHEN | Director | 08 May 2024 | Purchase | 4,916.4 | 10.17 | 50,000 | D |
06 Mar 2024 13:06 | XIVYX | Institutional Investment Strategy Fund | PAUKER MATTHEW | Principal Financial Officer, 10% | 06 Mar 2024 | Purchase | 120,000 | 10 | 1,200,000 | D |
06 Mar 2024 15:21 | XIVYX | Institutional Investment Strategy Fund | MCELHOE WENWEN | Director | 05 Mar 2024 | Purchase | 25,000 | 10 | 250,000 | D |
02 Apr 2024 11:07 | XHFIX | Hartford Schroders Private Opportunities Fund | GARDELLA LEE A | See Explanation of | 01 Apr 2024 | Purchase | 19,216 | 10.4 | 199,846 | D |
01 Dec 2023 11:28 | XHFIX | Hartford Schroders Private Opportunities Fund | HARTFORD FUNDS MANAGEMENT CO LLC | 10% | 01 Dec 2023 | Purchase | 396,275 | 10.094 | 4,000,000 | D |
01 Dec 2023 11:40 | XHFIX | Hartford Schroders Private Opportunities Fund | SCHRODER US HOLDINGS INC. | 10% | 01 Dec 2023 | Purchase | 396,275 | 10.094 | 4,000,000 | D |
20 Jun 2023 17:04 | XGN | EXAGEN Inc | TULLIS JAMES L L | 10% | 15 Jun 2023 | Purchase | 167 | 3.1105 | 519 | I |
16 May 2024 20:02 | XGN | EXAGEN Inc | ABALLI JOHN | President and CEO | 16 May 2024 | Purchase | 40,401 | 1.92 | 77,570 | I |
18 Oct 2023 16:05 | XGN | EXAGEN Inc | ABALLI JOHN | President and CEO | 17 Oct 2023 | Sale | 33,819 | 1.7451 | 59,018 | D |
08 Feb 2024 16:05 | XGN | EXAGEN Inc | ADAWI KAMAL | CFO and Corporate Secretary | 06 Feb 2024 | Sale | 6,738 | 1.9491 | 13,133 | D |
06 Mar 2024 16:05 | XGN | EXAGEN Inc | ADAWI KAMAL | CFO and Corporate Secretary | 04 Mar 2024 | Sale | 9,297 | 1.9089 | 17,747 | D |
06 Mar 2024 16:05 | XGN | EXAGEN Inc | ADAWI KAMAL | CFO and Corporate Secretary | 04 Mar 2024 | Sale | 3,487 | 1.9099 | 6,660 | D |
16 Jun 2023 16:17 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 15 Jun 2023 | Sale | 5,417 | 2.22 | 12,026 | D |
16 Jun 2023 16:15 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 15 Jun 2023 | Sale | 6,724 | 2.23 | 14,995 | D |
16 Jun 2023 16:24 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 15 Jun 2023 | Sale | 857 | 2.23 | 1,911 | D |
26 Jun 2023 16:13 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 23 Jun 2023 | Sale | 5,417 | 1.93 | 10,455 | D |
26 Jun 2023 16:11 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 23 Jun 2023 | Sale | 6,724 | 1.92 | 12,910 | D |
26 Jun 2023 16:15 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 23 Jun 2023 | Sale | 857 | 1.93 | 1,654 | D |
05 Jul 2023 16:05 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 30 Jun 2023 | Sale | 464 | 1.89 | 877 | D |
05 Jul 2023 16:04 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 30 Jun 2023 | Sale | 2,641 | 1.89 | 4,991 | D |
31 May 2023 17:05 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 31 May 2023 | Sale | 6,292 | 1.95 | 12,269 | D |
11 Aug 2023 19:26 | XFOR | X4 Pharmaceuticals Inc | STEWART MURRAY | Interim Chief Medical Officer | 10 Aug 2023 | Sale | 130,056 | 1.06 | 137,859 | D |
22 Aug 2023 16:09 | XFOR | X4 Pharmaceuticals Inc | WYZGA MICHAEL S | Director | 18 Aug 2023 | Purchase | 25,000 | 1.195 | 29,875 | D |
12 Sep 2023 16:04 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 08 Sep 2023 | Sale | 2,642 | 1.249 | 3,300 | D |
03 Nov 2023 16:39 | XFOR | X4 Pharmaceuticals Inc | TAVERAS ARTHUR | Chief Scientific Officer | 01 Nov 2023 | Sale | 67,695 | 0.73 | 49,417 | D |
03 Nov 2023 16:42 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 01 Nov 2023 | Sale | 230,645 | 0.73 | 168,371 | D |
03 Nov 2023 16:40 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 01 Nov 2023 | Sale | 67,695 | 0.73 | 49,417 | D |
03 Nov 2023 16:39 | XFOR | X4 Pharmaceuticals Inc | BALDRY MARK | Chief Commercial Officer | 01 Nov 2023 | Sale | 10,257 | 0.73 | 7,488 | D |
03 Nov 2023 17:26 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 03 Nov 2023 | Sale | 39,906 | 0.9 | 35,915 | D |
03 Nov 2023 17:26 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 01 Nov 2023 | Sale | 199,531 | 0.73 | 145,658 | D |
12 Feb 2024 17:03 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 12 Feb 2024 | Sale | 27,721 | 1.0091 | 27,973 | D |
12 Feb 2024 17:05 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 12 Feb 2024 | Sale | 21,695 | 1.0091 | 21,892 | D |
12 Feb 2024 17:23 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 12 Feb 2024 | Sale | 3,683 | 1.007 | 3,709 | D |
12 Feb 2024 17:23 | XFOR | X4 Pharmaceuticals Inc | TAVERAS ARTHUR | Chief Scientific Officer | 12 Feb 2024 | Sale | 787 | 1.0072 | 793 | D |
11 Mar 2024 17:20 | XFOR | X4 Pharmaceuticals Inc | TAVERAS ARTHUR | Chief Scientific Officer | 11 Mar 2024 | Sale | 14,235 | 0.8818 | 12,552 | D |
11 Mar 2024 17:20 | XFOR | X4 Pharmaceuticals Inc | RAGAN PAULA | President and CEO | 11 Mar 2024 | Sale | 49,678 | 0.8828 | 43,856 | D |
11 Mar 2024 17:19 | XFOR | X4 Pharmaceuticals Inc | MOSTAFA ADAM S. | Chief Financial Officer | 11 Mar 2024 | Sale | 52,500 | 0.8828 | 46,347 | D |
11 Mar 2024 17:19 | XFOR | X4 Pharmaceuticals Inc | DIBIASE MARY | Chief Operating Officer | 11 Mar 2024 | Sale | 15,409 | 0.882 | 13,591 | D |
10 May 2024 16:37 | XFLT | XAI Octagon Floating Rate & Alternative Income Trust | SPENCE JOHN YOGI | Advisor Personnel | 09 May 2024 | Purchase | 3,417 | 7.13 | 24,363 | I |
10 May 2024 16:37 | XFLT | XAI Octagon Floating Rate & Alternative Income Trust | SPENCE JOHN YOGI | Advisor Personnel | 10 May 2024 | Purchase | 3,450 | 7.13 | 24,598 | I |
10 May 2024 16:48 | XFLT | XAI Octagon Floating Rate & Alternative Income Trust | BROMBACH THEODORE J | President & CEO | 09 May 2024 | Purchase | 3,417 | 7.13 | 24,363 | I |
10 May 2024 16:48 | XFLT | XAI Octagon Floating Rate & Alternative Income Trust | BROMBACH THEODORE J | President & CEO | 10 May 2024 | Purchase | 3,450 | 7.13 | 24,598 | I |
16 Nov 2023 12:04 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | BROMBACH THEODORE J | President & CEO | 13 Nov 2023 | Purchase | 289 | 7.08 | 2,046 | I |
16 Nov 2023 12:05 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | SPENCE JOHN YOGI | Adviser Personnel | 13 Nov 2023 | Purchase | 289 | 7.08 | 2,046 | I |
06 Dec 2023 17:03 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | SPENCE JOHN YOGI | Adviser Personnel | 05 Dec 2023 | Purchase | 6,000 | 6.89 | 41,340 | I |
06 Dec 2023 17:01 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | BROMBACH THEODORE J | President & CEO | 05 Dec 2023 | Purchase | 6,000 | 6.89 | 41,340 | I |
13 Dec 2023 13:02 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | SPENCE JOHN YOGI | Adviser Personnel | 12 Dec 2023 | Purchase | 825 | 7.05 | 5,816 | I |
13 Dec 2023 13:01 | XFLT | XAI Octagon Floating Rate & Alternative Income Term Trust | BROMBACH THEODORE J | President & CEO | 12 Dec 2023 | Purchase | 825 | 7.05 | 5,816 | I |
09 Aug 2023 18:57 | XERS | Xeris Biopharma Holdings Inc | EDICK PAUL R | See Remarks | 09 Aug 2023 | Purchase | 10,000 | 2.3794 | 23,794 | D |
10 May 2024 16:04 | XERS | Xeris Biopharma Holdings Inc | SCHMID JOHN P. | Director | 10 May 2024 | Purchase | 5,400 | 1.91 | 10,314 | I |
15 Nov 2023 16:13 | XERS | Xeris Biopharma Holdings Inc | PERSKY MARLA | Director | 14 Nov 2023 | Purchase | 6,370 | 1.5789 | 10,058 | I |
17 Nov 2023 17:58 | XERS | Xeris Biopharma Holdings Inc | SHANNON JOHN PATRICK JR | See Remarks | 17 Nov 2023 | Purchase | 30,769 | 1.638 | 50,400 | D |
17 Nov 2023 18:35 | XERS | Xeris Biopharma Holdings Inc | SCHMID JOHN P. | Director | 16 Nov 2023 | Purchase | 6,500 | 1.51 | 9,815 | I |
21 Nov 2023 16:16 | XERS | Xeris Biopharma Holdings Inc | PIEPER STEVEN | See Remarks | 20 Nov 2023 | Purchase | 28,000 | 1.95 | 54,600 | D |
21 Nov 2023 16:20 | XERS | Xeris Biopharma Holdings Inc | HALKUFF DAWN | Director | 20 Nov 2023 | Purchase | 5,410 | 1.84 | 9,954 | I |
29 Nov 2023 16:09 | XERS | Xeris Biopharma Holdings Inc | SHERMAN JEFFREY W | Director | 27 Nov 2023 | Purchase | 5,400 | 1.87 | 10,098 | I |
14 Mar 2024 21:03 | XERS | Xeris Biopharma Holdings Inc | SCHMID JOHN P. | Director | 14 Mar 2024 | Purchase | 4,500 | 2.16 | 9,720 | I |
26 May 2023 19:10 | XENE | Xenon Pharmaceuticals Inc | MORTIMER IAN | PRESIDENT & CEO | 24 May 2023 | Sale | 17,069 | 41.44 | 707,339 | D |
26 May 2023 19:10 | XENE | Xenon Pharmaceuticals Inc | MORTIMER IAN | PRESIDENT & CEO | 24 May 2023 | Sale | 13,179 | 41.37 | 545,215 | D |
26 May 2023 19:10 | XENE | Xenon Pharmaceuticals Inc | MORTIMER IAN | PRESIDENT & CEO | 24 May 2023 | Sale | 1,407 | 41.49 | 58,376 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 30 May 2023 | Sale | 18,006 | 38.63 | 695,572 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 30 May 2023 | Sale | 19,000 | 39.9 | 758,100 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 31 May 2023 | Sale | 12,000 | 38.53 | 462,360 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 31 May 2023 | Sale | 23,670 | 38.81 | 918,633 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 31 May 2023 | Sale | 26,856 | 38.69 | 1,039,059 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 01 Jun 2023 | Sale | 7,458 | 38.97 | 290,638 | D |
01 Jun 2023 19:25 | XENE | Xenon Pharmaceuticals Inc | PIMSTONE SIMON N. | Director | 01 Jun 2023 | Sale | 24,255 | 38.78 | 940,609 | D |
24 Aug 2023 16:33 | XENE | Xenon Pharmaceuticals Inc | SVORONOS DAWN | Director | 24 Aug 2023 | Sale | 25,000 | 38.7 | 967,500 | D |
15 Dec 2023 17:38 | XENE | Xenon Pharmaceuticals Inc | PATOU GARY | Director | 13 Dec 2023 | Sale | 5,100 | 38.94 | 198,594 | D |
15 Dec 2023 17:38 | XENE | Xenon Pharmaceuticals Inc | PATOU GARY | Director | 13 Dec 2023 | Sale | 2,303 | 39.1 | 90,047 | D |
15 Dec 2023 17:38 | XENE | Xenon Pharmaceuticals Inc | PATOU GARY | Director | 13 Dec 2023 | Sale | 3,977 | 39.84 | 158,444 | D |
15 Dec 2023 17:38 | XENE | Xenon Pharmaceuticals Inc | PATOU GARY | Director | 13 Dec 2023 | Sale | 7,598 | 41.05 | 311,898 | I |
15 Dec 2023 21:50 | XENE | Xenon Pharmaceuticals Inc | PATOU GARY | Director | 14 Dec 2023 | Sale A | 7,598 | 41.05 | 311,898 | I |
08 Mar 2024 17:28 | XENE | Xenon Pharmaceuticals Inc | GANNON STEVEN | Director | 07 Mar 2024 | Sale | 1,000 | 46.45 | 46,450 | D |
08 Mar 2024 17:28 | XENE | Xenon Pharmaceuticals Inc | GANNON STEVEN | Director | 07 Mar 2024 | Sale | 5,000 | 46.25 | 231,250 | D |
08 Mar 2024 17:28 | XENE | Xenon Pharmaceuticals Inc | GANNON STEVEN | Director | 07 Mar 2024 | Sale | 5,000 | 46.3025 | 231,512 | D |
08 Mar 2024 17:28 | XENE | Xenon Pharmaceuticals Inc | GANNON STEVEN | Director | 07 Mar 2024 | Sale | 2,000 | 46.2012 | 92,402 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)